In a regulatory filing, Zydus Cadila said it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.
Subscribe to:
Post Comments (Atom)
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
Google has tried for years to get Samsung, the world#39;s leading mobile device maker by units sold, to drop its own services and give grea...
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
No comments:
Post a Comment